Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Primary tabs

field_vote: 
Average: 7 (1 vote)
Publication type: 
Number of included patients: 
References: 
Therapeutic intervention: 
Disease(s): 
Therapeutic Substance(s): 

Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. Epub 2008 Jun 17.
 
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
 
Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C.

 
Department
of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey
9E, Boston, MA 02114, USA.

BACKGROUND:
A 48-year-old man presented to a neurologist with complaints of
bilateral hearing loss and tinnitus. The patient was a member of a
large family affected by neurofibromatosis type 2 and first noted
hearing loss 10 years before presentation.
INVESTIGATIONS: Medical and
neurological examination, MRI scan of the brain and spinal cord,
pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring,
City University of New York topic-related sentences test, noise/voice
test of minimal auditory capability battery.
DIAGNOSIS: Progressive
neurofibromatosis-type-2-related vestibular schwannomas.
MANAGEMENT:
Annual cranial MRI and audiology, surgical resection of right
vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib
therapy for progressive left vestibular schwannoma.